Status:
COMPLETED
Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Eosinophilic Esophagitis
Eligibility:
All Genders
16-80 years
Phase:
NA
Brief Summary
This is a prospective single center clinical trial of allergen-specific immune signature-guided dietary elimination therapy to assess the clinical effectiveness of this technique.
Detailed Description
This is a prospective single center clinical trial of allergen-specific immune signature-guided dietary elimination therapy to assess the clinical effectiveness of this technique. Potential subjects ...
Eligibility Criteria
Inclusion
- Age 16-80 years old
- Meet one of the following:
- Active EoE as per consensus guidelines OR
- Undergoing upper endoscopy for a clinical suspicion of EoE
- No prior history of dietary elimination therapy
Exclusion
- Concomitant eosinophilic gastroenteritis
- Any corticosteroid exposure in the 4 weeks prior to their baseline endoscopic exam
- Previous esophageal surgery
- Medical instability that precludes safely performing upper endoscopy
- Inability to read or understand English
- Pregnant women
Key Trial Info
Start Date :
April 21 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2018
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT02722148
Start Date
April 21 2016
End Date
April 1 2018
Last Update
April 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UNC Chapel Hill
Chapel Hill, North Carolina, United States, 27599